What Every Clinical Research Site Owner Should Know Before Selling

Most clinical research site owners don't lose value because they run bad businesses.

They lose it because they weren't prepared when the market shifted — and by the time they started thinking seriously about their options, their leverage was already gone.

This isn't a story about failure. The founders who walk away from the table with disappointing outcomes are often the same people who built something genuinely impressive — strong teams, loyal sponsors, years of consistent enrollment. The problem isn't what they built. It's that they never took the time to see their business the way a buyer would. And in M&A, that gap between how you see your business and how a buyer sees it is exactly where value gets left on the table.

This post is about closing that gap — so that when the right opportunity shows up, you're not reacting to it. You're evaluating it calmly, confidently, and on your own terms.

What's Happening in Clinical Research Right Now

The clinical research industry is in the middle of a significant structural shift, and it's moving faster than most independent site owners realize.

Private equity, strategic acquirers, and large site networks are entering the space at an accelerating pace. The reason isn't complicated: they see a highly fragmented industry with recurring contract revenue, strong and growing pharma demand, and real potential to scale. So they're doing what capital does when it spots a fragmented market — they're building platforms. Multi-site, multi-therapeutic, regional and national networks that can offer sponsors the scale, speed, and consistency that a single independent site often can't.

Right now, we are still in the relatively early stages of that consolidation. That matters, because it means independent site owners currently have something that won't last indefinitely: genuine leverage. Multiple buyers are competing for quality assets. Multiples are still strong for well-positioned sites. And founders have real choice about who they partner with and on what terms.

But the window doesn't stay open forever. As networks grow and platforms scale, fewer independent sites remain as acquisition targets. Buyers become more selective. They fill their geographic and therapeutic gaps and begin expanding organically rather than through acquisition. Multiples compress. The leverage that exists today gradually shifts to the buyer's side of the table.

The founders who understand this dynamic — and prepare accordingly — are the ones who end up with the best outcomes.

What a Deal Actually Looks Like

Before going any further, it's worth addressing a misconception that holds a lot of site owners back from even having the conversation.

When most people hear "private equity acquisition," they picture a transaction where you hand over the keys, take a check, and walk away. That's rarely what happens in today's lower middle market, and it's almost never what happens in clinical research.

Most deals today are structured as a partnership. There is meaningful cash at close — often the largest single sum a founder has ever received — but there's typically also an equity component, where a portion of proceeds are rolled into the acquiring platform. This structure exists because buyers want founders to remain invested in the business's success, and because founders benefit from continued upside as the platform grows.

That rolled equity is what creates what's often called the "second bite of the apple." Because these platforms are still actively consolidating and growing, the equity you retain today can be worth significantly more at a second liquidity event — when the platform itself is eventually sold or recapitalized, typically three to five years later. We've seen that rolled equity double or triple in value in that timeframe, meaning the total outcome for a founder who sells today can far exceed what a simple cash sale would have produced.

Understanding this structure changes the conversation entirely. You're not just asking "what is my site worth today?" You're asking "what is the total outcome I can achieve over the next several years, and which partner gives me the best chance of getting there?"

What Buyers Are Actually Paying For

Here is the single most important thing to understand about how buyers evaluate clinical research sites:

They don't pay for potential. They pay for predictability.

A buyer looking at your business is fundamentally trying to answer one question: how confident can I be that this business will perform the way it has performed — or better — after I acquire it? Every element of their due diligence process is oriented around that question. And the more clearly and confidently you can answer it, the more your business is worth.

Predictability shows up in several specific areas:

Pipeline visibility. Buyers want to see a clearly documented picture of your study history and your forward pipeline — completed studies, awarded studies, and what's in active discussion — broken down by sponsor, revenue, and therapeutic area. They're also looking at concentration risk. If the majority of your revenue comes from one or two sponsor relationships, that's a vulnerability. Diversification across sponsors and therapeutic areas signals stability and reduces the risk premium a buyer has to build into their offer.

Financial clarity. Clean, well-organized financials are non-negotiable for a premium outcome. Buyers need to understand your EBITDA clearly, see where your revenue comes from, understand your cost structure, and have confidence in your projections. Messy or unclear financials don't just slow the process down — they create doubt, and doubt lowers price. If you can't explain your numbers simply and confidently, a buyer won't be able to either, and they'll price that uncertainty into their offer.

Business development systems. Where do your studies come from? If the honest answer is "mostly through one person's relationships," that's a key man risk problem. Buyers want to see a repeatable, trackable system for generating new business — one that doesn't depend entirely on any single individual remaining at the company. A documented BD process that has produced consistent results over time is a genuine value driver.

Patient recruitment infrastructure. Patient recruitment is one of the most scrutinized areas in any clinical research site acquisition. Buyers want to see a real patient database, a defined and repeatable recruitment process, and ideally a track record of meeting or exceeding enrollment targets. Sites that can reliably predict their enrollment performance command meaningfully higher multiples than those where every study feels like starting from scratch.

Key man risk. This is one of the most common and most damaging value detractors in clinical research site transactions. If your site's operations, sponsor relationships, or patient recruitment are heavily dependent on a single Principal Investigator — especially if that person is the owner — buyers will apply a significant risk discount. The question they're asking is simple: what happens to this business if that person steps back or leaves? If the answer involves significant uncertainty, that uncertainty shows up in the offer.

A credible growth story. Buyers aren't just acquiring what exists today — they're acquiring a platform they intend to grow. That means they want to understand not just where your business has been, but where it's going and how. A clear, specific, and credible growth thesis — new therapeutic areas you're positioned to enter, sponsors you're in active conversations with, capacity you have to take on additional studies — adds real value to your business in a buyer's eyes.

The Practical Side: What Preparation Actually Looks Like

Understanding what buyers value is the first step. The second is doing the work to make sure your business reflects those values clearly and completely before you go to market.

On the financial side, this means getting your books in order well in advance of any process — ideally at least a year out. That includes clean, reviewed financial statements, a clear picture of your adjusted EBITDA with well-documented add-backs, and a forward projection that's grounded in real pipeline visibility rather than optimism.

On the operational side, it means looking honestly at your key man dependencies and taking steps to reduce them where possible. That might mean building out your Sub-Investigator bench, documenting your operational processes so they're not entirely dependent on institutional knowledge, or formalizing your BD and recruitment systems in ways that make them clearly transferable.

It also means assembling the right advisors before you need them. An experienced M&A advisor, an attorney who understands healthcare transactions, and a wealth manager who can help you think through the tax and financial planning implications of a liquidity event — having these relationships in place before you're in the middle of a process makes an enormous difference in both outcomes and stress levels.

None of this is about manufacturing a business that looks better than it is. It's about making sure the business you've actually built is presented as clearly and compellingly as possible — so that buyers are paying for the real value you've created, not discounting for things that are either manageable or already improving.

Why Preparation Is Really About Control

Here's the thing about getting prepared: it doesn't obligate you to do anything.

Founders who have done the work to understand their business from a buyer's perspective, get their financials in order, reduce key man risk, and build a credible growth story aren't just more attractive to buyers. They're also in a fundamentally different position when an opportunity presents itself.

Instead of feeling pressured to move quickly because the offer on the table is the only one you've seen, you can evaluate it carefully. Instead of accepting terms that don't quite work because you're not sure you could do better, you can negotiate from a position of knowledge. Instead of reacting to the market, you're participating in it on your own terms.

That's the real goal of preparation — not an exit, but optionality. The ability to say yes to the right deal, and no to the wrong one, with full confidence in either decision.

The market for clinical research sites will continue to evolve. No one can predict exactly how buyer appetite, valuations, or deal structures will look in two or three years. But what you can control is how ready you are when opportunity arrives — and whether the business you've built is positioned to capture the full value it deserves.

Hannah Huke is a Managing Director at Evergreen M&A, where she works with healthcare and clinical research founders on mergers and acquisitions — from initial valuation through close. If you'd like to understand what your site might look like through a buyer's lens, reach out at hannah@evergreenforfounders.com or visit evergreenforfounders.com.